Anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound based on neutrophil nano-vesicles as well as preparation method and application of anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound

Through the complex based on neutrophil nanovesicles, the photodynamic therapy-related drugs and ranibizumab, the multi-target and multi-step treatment of corneal neovascularization has been achieved, significantly improving the therapeutic effect.

CN119701010AActive Publication Date: 2025-03-28EYE HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY (SHANDONG EYE HOSPITAL)
6 Cites 1 Cited by

Patent Information

Application Number
CN202411929589.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-25
Publication Date
2025-03-28
Estimated Expiration
2044-12-25

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat corneal neovascularization, and drugs targeting VEGF are easily excreted from the body, resulting in the need for repeated administration, and single-target treatment cannot completely inhibit the occurrence of neovascularization.

Method used

Using a complex based on anti-inflammatory and anti-vascular bidirectional trapping combined with self-luminescent dynamics, the phospholipid bilayer of neutrophil nanovesicles is used to carry bis(n-amyl 2,4,5-trichlorosalicylate)oxalate and dihydrophen E6, and the connection of ranibizumab on the outer surface of the vesicles, to achieve anti-inflammatory and anti-vascular effects.

Benefits of technology

The complex exerts efficacy through a variety of pathways, including spontaneous targeting of inflammatory sites, trapping inflammatory factors, inhibiting vascular endothelial growth factors and destroying vascular endothelial cells through photodynamic therapy, significantly reducing the concentration of inflammatory factors and inhibiting the formation of corneal neovascularization.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides an anti-inflammatory and anti-vascular bidirectional trapping combined self-luminous power compound based on neutrophil nano-vesicles as well as a preparation method and application thereof, and belongs to the technical field of biological medicine manufacturing. The compound takes a neutrophil nano-vesicle as a carrier, and is also loaded with bis (2, 4, 5-trichlorosalicylic acid n-amyl ester) oxalate (CPPO) and a photosensitizer Ce6, and meanwhile, the surface of the compound is modified with ranibizumab through ketal mercaptan responded by ROS (reactive oxygen species). The compound has the characteristics of trapping anti-inflammatory factors and spontaneously targeting corneal neovascularization diseased regions, Ranibizumab is responsively released on the basis of ROS to be combined with vascular endothelial growth factors, the anti-angiogenesis function is achieved, meanwhile, chemical energy generated by CPPO under the high-oxygen condition stimulates Ce6 to generate singlet oxygen, and therefore the vascular endothelial cell tubulogenesis capacity is inhibited. The invention provides a new means for treatment of eye disease related diseases.
Need to check novelty before this filing date? Find Prior Art